We Offer Worldwide Shipping
Login Wishlist

Sennoside B

$93

  • Brand : BIOFRON

  • Catalogue Number : BF-S2017

  • Specification : 98%

  • CAS number : 128-57-4

  • Formula : C42H38O20

  • Molecular Weight : 862.74

  • PUBCHEM ID : 91440

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-S2017

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

862.74

Appearance

Yellow needle crystal

Botanical Source

Rheum palmatum,Senna alexandrina

Structure Type

Flavonoids

Category

Standards;Natural Pytochemical;API

SMILES

C1=CC2=C(C(=C1)OC3C(C(C(C(O3)CO)O)O)O)C(=O)C4=C(C2C5C6=C(C(=CC=C6)OC7C(C(C(C(O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)C(=O)O)C=C(C=C4O)C(=O)O

Synonyms

SennosideB/[9,9'-Bianthracene]-2,2'-dicarboxylic acid, 5,5'-bis(β-D-glucopyranosyloxy)-9,9',10,10'-tetrahydro-4,4'-dihydroxy-10,10'-dioxo-, (9R,9'S)-/Sennoside B/(9R,9'S)-5,5'-Bis(β-D-glucopyranosyloxy)-4,4'-dihydroxy-10,10'-dioxo-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid/(9R,9'S)-4,4'-Dihydroxy-10,10'-dioxo-5,5'-bis{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid

IUPAC Name

(9S)-9-[(9R)-2-carboxy-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid

Density

1.7±0.1 g/cm3

Solubility

Methanol; DMF

Flash Point

348.6±27.8 °C

Boiling Point

1144.8±65.0 °C at 760 mmHg

Melting Point

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2932200000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:128-57-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

31816471

Abstract

Sennoside B is a specific dianthrone compound extracted from senna, which is widely used as a stimulant laxative but has potential side effects. This study aimed to obtain the metabolic and pharmacokinetic data of sennoside B. The metabolic profiles of sennoside B were obtained from rat plasma, urine, bile and feces by an ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS). As a result, 14 metabolites were structurally identified and the proposed metabolic pathways of sennoside B included hydrolysis to aglycones, release of rhein-type anthrone, and extensive conjugation. As the only compound detected in the plasma samples after intravenous and intragastric administrations, the prototype was selected as the plasma marker in the pharmacokinetic study. A simple and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed for the quantitation of sennoside B in rat plasma. The linear range of sennoside B was 5-1000 ng/mL (R2 ≥ 0.991) and the lowest limit of quantification (LLOQ) was 5 ng/mL. The intra- and inter- precisions of the assay were less than 10%, whereas accuracy ranged from 85.80% to 103.80%. The extraction recovery, matrix effect and stability of sennoside B were within acceptable limits. The established method was well validated and successfully applied to the pharmacokinetic study of sennoside B. The oral absolute bioavailability of sennoside B was calculated as 3.60% and the value apparent volume of distribution of intravenous and intragastric administrations were 32.47 ± 10.49 L/kg and 7646 ± 1784 L/kg, respectively. The maximum plasma concentrations were 212.6 ± 50.9 μg/L and 14.06 ± 2.73 μg/L for intravenous and intragastric dosing groups, respectively. According to the current results of pharmacokinetic and metabolic profiling studies, metabolites with high abundance in tissues would be the next object in the pharmacokinetic study of sennoside B.

KEYWORDS

Metabolites; Pharmacokinetic; Sennoside B; UPLC-MS/MS; UPLC-Q-TOF-MS.

Title

Pharmacokinetic and Metabolic Profiling Studies of Sennoside B by UPLC-MS/MS and UPLC-Q-TOF-MS

Author

Hongyu Wu 1 , Feng Feng 1 , Xiunan Jiang 1 , Binchuan Hu 1 , Jieying Qiu 1 , CaiHong Wang 2 , Zheng Xiang 3

Publish date

2020 Feb 5

PMID

29963161

Abstract

Osteosarcoma is a mesenchymally derived, high-grade bone sarcoma that is the most frequently diagnosed primary malignant bone tumor. Today, chemoprevention is regarded as a promising and realistic approach in the prevention of human cancer. Previous studies have suggested ellagic acid (EA) and Sennoside B have potential in this regard. The aim of the present study was to elucidate the anti-osteosarcoma effects of EA and Sennoside B by using Saos-2 and MG63 osteosarcoma cells. It was identified that EA or Sennoside B treatment could inhibit the growth, migration and invasion of the cells, and induce G1 cell cycle arrest by repressing the transcription of c-Jun. These results may provide a cellular basis for the application of EA or Sennoside B in the treatment of patients with osteosarcoma.

KEYWORDS

c-Jun; ellagic acid; growth; migration; osteosarcoma; sennoside B.

Title

Ellagic Acid and Sennoside B Inhibit Osteosarcoma Cell Migration, Invasion and Growth by Repressing the Expression of c-Jun

Author

Wei Xu 1 , Jinjin Xu 2 , Ting Wang 1 , Weibo Liu 1 , Haifeng Wei 1 , Xinghai Yang 1 , Wangjun Yan 1 , Wang Zhou 1 , Jianru Xiao 1

Publish date

2018 Jul

PMID

26336586

Abstract

Sennoside A (erythro) and sennoside B (threo) are dianthrone glycosides and diastereomers. We investigated their abilities to prevent the gastric lesions associated with diseases, such as, gastritis and gastric ulcer. To elucidate their gastroprotective effects, the inhibitions of HCl•EtOH-induced gastritis and indomethacin-induced gastric ulcers were assessed in rats. It was observed that both sennoside A and sennoside B increased prostaglandin E2 (PGE2) levels and inhibited H(+)/K(+)-ATPase (proton pump). In a rat model, both compounds reduced gastric juice, total acidity and increased pH, indicating that proton pump inhibition reduces gastric acid secretion. Furthermore, sennoside A and B increased PGE2 in a concentration-dependent manner. In a gastric emptying and intestinal transporting rate experiment, both sennoside A and sennoside B accelerated motility. Our results thus suggest that sennoside A and sennoside B possess significant gastroprotective activities and they might be useful for the treatment of gastric disease.

KEYWORDS

Gastric lesion; H+/K+-ATPase; Prostaglandin E2; Sennoside A; Sennoside B.

Title

Gastroprotective Activities of Sennoside A and Sennoside B via the Up-Regulation of Prostaglandin E2 and the Inhibition of H(+)/K(+)-ATPase

Author

In Young Hwang 1 , Choon Sik Jeong 1

Publish date

2015 Sep


Description :

Sennoside B is an anthraquinone glycoside, found in large quantities in leaves and pods of Senna (Cassia angustifolia)[1]. Sennoside B can inhibit PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway[2].